{
    "nct_id": "NCT04257500",
    "official_title": "Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/obese Women with PCOS",
    "inclusion_criteria": "* Diagnosis of PCOS according to Rotterdam criteria, with at least 2 of 3 of the following criteria: oligomenorrhea (≤8 periods per year), clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound\n* Body mass index ≥25 and ≤45 kg/m2\n* In good general health according to the investigators' discretion\n* Willing to avoid pregnancy for the duration of the study\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 40 Years",
    "exclusion_criteria": "* Current pregnancy or desire for pregnancy during course of study\n* Current breastfeeding\n* Second-trimester pregnancy within four weeks prior to initiation of NuvaRing or third-trimester pregnancy within 6 months prior to initiation of NuvaRing\n* Use of hormonal contraception within four weeks prior to initiation of NuvaRing\n* Diagnosis of metabolic syndrome. Metabolic syndrome will be defined according to the updated Adult Treatment Panel III as 3 or more of the following criteria: blood pressure ≥130/85 mm Hg, waist circumference >35 inches, fasting glucose ≥110 mg/dL, TG ≥150 mg/dL, HDL-C <50 mg/dL.\n* Contraindications to NuvaRing use:\n\n  * Age ≥ 35 plus tobacco use\n  * Current or past deep vein thrombosis or pulmonary embolism\n  * Cerebrovascular disease\n  * Coronary artery disease\n  * Thrombogenic valvular or rhythm diseases of the heart (such as subacute bacterial endocarditis with valvular disease or atrial fibrillation)\n  * Inherited or acquired coagulopathy\n  * Headaches with focal neurological symptoms or migraine headaches with aura\n  * Age ≥ 35 plus any migraine headaches\n  * Liver tumors, benign or malignant\n  * Undiagnosed abnormal uterine bleeding\n  * Current or past breast cancer or other estrogen- or progestin-sensitive cancer\n  * Hypersensitivity to any of the components of NuvaRing\n  * Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir\n* Medical comorbidities:\n\n  * 21-hydroxylase deficiency, congenital adrenal hyperplasia\n  * Untreated thyroid disease\n  * Untreated hyperprolactinemia\n  * Type 1 or 2 diabetes mellitus\n  * Uncontrolled liver disease\n  * Uncontrolled renal disease\n  * Current alcohol abuse\n  * Hypertension ≥ 140 mm Hg average systolic or ≥ 90 mm Hg average diastolic in women using anti-hypertensive medication\n  * Hypertension ≥ 150 mm Hg average systolic or ≥ 100 mm Hg average diastolic in women not using anti-hypertensive medication\n  * History of or current gynecologic cancer\n  * Triglycerides >=250 mg/dL\n  * Current use of lipid-lowering or weight loss agents\n  * Participation in any study of an investigational drug or device or biologic agent within 30 days\n  * Suspected adrenal or ovarian tumor secreting androgens\n  * Suspected Cushing's syndrome\n  * Bariatric surgery within 12 months\n  * Other medical concerns that in the judgment of the investigator may compromise safety of the participant or confound the reliability of compliance and information acquired in this study",
    "miscellaneous_criteria": ""
}